RSLS Insider Trading

Insider Ownership Percentage: 8.10%
Insider Buying (Last 12 Months): $18,400.00
Insider Selling (Last 12 Months): $51,957.29

ReShape Lifesciences Insider Trading History Chart

This chart shows the insider buying and selling history at ReShape Lifesciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ReShape Lifesciences Share Price & Price History

Current Price: $6.95
Price Change: Price Decrease of -10.09 (-59.21%)
As of 02/6/2023 01:00 AM ET

This chart shows the closing price history over time for RSLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

ReShape Lifesciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2022Thomas StankovichCFOSell8,393$0.27$2,266.11332,761View SEC Filing Icon  
10/4/2022Thomas StankovichCFOSell8,293$0.28$2,322.04338,670View SEC Filing Icon  
9/6/2022Thomas StankovichCFOSell4,828$0.39$1,882.92346,963View SEC Filing Icon  
8/5/2022Barton P. BandyCEOSell11,674$0.47$5,486.78773,098View SEC Filing Icon  
8/5/2022Thomas StankovichCFOSell4,728$0.47$2,222.16351,791View SEC Filing Icon  
7/1/2022Barton P. BandyCEOSell11,442$0.55$6,293.10784,772View SEC Filing Icon  
7/1/2022Thomas StankovichCFOSell4,630$0.55$2,546.50356,519View SEC Filing Icon  
6/1/2022Barton P. BandyCEOSell11,309$0.95$10,743.55796,214View SEC Filing Icon  
5/31/2022Thomas StankovichCFOBuy20,000$0.92$18,400.00365,627View SEC Filing Icon  
4/1/2022Barton P. BandyCEOSell11,063$1.13$12,501.19818,940View SEC Filing Icon  
4/1/2022Thomas StankovichCFOSell5,038$1.13$5,692.94350,156View SEC Filing Icon  
1/31/2022Barton P. BandyCEOSell8,324$1.22$10,155.28View SEC Filing Icon  
1/31/2022Thomas StankovichCFOSell3,684$1.22$4,494.48View SEC Filing Icon  
1/4/2022Barton P. BandyCEOSell7,150$1.79$12,798.50View SEC Filing Icon  
1/4/2022Thomas StankovichCFOSell3,171$1.78$5,644.38View SEC Filing Icon  
12/2/2021Barton P. BandyCEOSell13,427$1.83$24,571.41View SEC Filing Icon  
12/2/2021Thomas StankovichCFOSell4,304$1.83$7,876.32View SEC Filing Icon  
11/18/2021Thomas StankovichCFOBuy20,000$2.02$40,400.00View SEC Filing Icon  
11/2/2021Barton P. BandyCEOSell13,505$2.69$36,328.45View SEC Filing Icon  
11/2/2021Thomas StankovichCFOSell4,320$2.69$11,620.80View SEC Filing Icon  
10/1/2021Barton P. BandyCEOSell12,565$2.77$34,805.05View SEC Filing Icon  
10/1/2021Thomas StankovichCFOSell3,660$2.76$10,101.60View SEC Filing Icon  
9/10/2021Barton P. BandyCEOSell294,494$2.89$851,087.66960,100View SEC Filing Icon  
9/10/2021Dan W. GladneyDirectorSell200,000$2.99$598,000.00View SEC Filing Icon  
9/10/2021Thomas StankovichCFOSell48,366$2.89$139,777.74315,995View SEC Filing Icon  
8/30/2021Thomas StankovichCFOBuy15,000$3.43$51,450.0032,613View SEC Filing Icon  
8/20/2021Thomas StankovichCFOBuy15,000$3.22$48,300.0017,613View SEC Filing Icon  
12/4/2020Armistice Capital Master FundMajor ShareholderBuy6,400$4.16$26,624.00
9/22/2020Armistice Capital Master FundMajor ShareholderBuy3,300$4.13$13,629.00
8/20/2020Armistice Capital Master FundMajor ShareholderBuy9,998$3.13$31,293.74
See Full Table

SEC Filings (Institutional Ownership Changes) for ReShape Lifesciences (OTCMKTS:RSLS)

3.29% of ReShape Lifesciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RSLS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

ReShape Lifesciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Vanguard Group Inc.118,607$36K0.0%-76.4%0.491%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC44,697$26K0.0%N/A0.240%Search for SEC Filing on Google Icon
5/11/2022GSA Capital Partners LLP36,490$43K0.0%N/A0.196%Search for SEC Filing on Google Icon
11/15/2021Sassicaia Capital Advisers LLC10,000$29K0.1%N/A0.063%Search for SEC Filing on Google Icon
8/17/2021Armistice Capital LLC816,527$4.08M0.1%N/A24.447%Search for SEC Filing on Google Icon
8/16/2021State Street Corp109,999$0.55M0.0%N/A3.293%Search for SEC Filing on Google Icon
8/13/2021Alpine Global Management LLC17,000$85K0.0%N/A0.509%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC23,277$0.12M0.0%N/A0.697%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.51,120$0.26M0.0%N/A1.531%Search for SEC Filing on Google Icon
11/13/2018Renaissance Technologies LLC2,287,729$0.10M0.0%N/A3,812.882%Search for SEC Filing on Google Icon
8/13/2018International Biotechnology Trust PLC52,546$0.12M0.0%-93.3%0.824%Search for SEC Filing on Google Icon
2/15/2018Anson Funds Management LP219,016$0.32M0.2%N/A0.731%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
ReShape Lifesciences logo
ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShapeCare and Diabetes Bloc-Stim Neuromodulation Device. The company was founded in December 2002 and is headquartered in San Clemente, CA.
Read More on ReShape Lifesciences

Today's Range

Now: $6.95
Low: $6.35
High: $7.45

50 Day Range

MA: $5.15
Low: $0.11
High: $17.04

52 Week Range

Now: $6.95
Low: $5.40
High: $77.00

Volume

5,390,390 shs

Average Volume

1,344,093 shs

Market Capitalization

$3.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ReShape Lifesciences?

ReShape Lifesciences' top insider shareholders include:
  1. Barton P Bandy (CEO)
  2. Barton P Bandy (CEO)
  3. Thomas Stankovich (CFO)
  4. Armistice Capital, Llc (Major Shareholder)
  5. Dan W Gladney (Director)
Learn More about top insider investors at ReShape Lifesciences.